NSEInvestor Presentation18 Jun 2026 · 18 Jun 2026, 09:52 am
Investor Presentation
Procter & Gamble Health Limited · PGHL
✦ AI Summary▲ PositiveResults
Procter & Gamble Health Limited has informed the Exchange about Investor Presentation, highlighting strong FY 2025-26 performance, integrated growth strategy, and portfolio performance drives brand choice superiority.
Analysis Scores
Earnings Impact8/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact9/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Procter & Gamble Health Limited has informed the Exchange about Investor Presentation
Attachments (1)
📄pdf
Download →
PGHL_18062026095119_PGHL__Analyst_Meet_-Presentation.pdf
View document text
Date : June 18, 2026
To, To,
The Corporate Relations Department The Listing Department
The BSE Limited The National Stock Exchange of India Limited
Department of Corporate Services Exchange Plaza, Plot No. C/1, G Block,
Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East),
Dalal Street, Mumbai – 400001 Mumbai – 400051
Ref:- Scrip ID: - 500126 Ref:- Scrip Code:- PGHL
Dear Sir / Madam,
Sub: Analysts/Institutional Investors – Presentation
This has reference to the intimation dated June 4, with respect to the virtual connect with analysts/
institutional investors to be held today, Thursday, June 18, 2026, at 2:30 p.m. (IST).
Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed
herewith is the presentation for the above meeting with analysts/ institutional investors.
This is for your record.
Thanking you,
Yours faithfully,
For Procter & Gamble Health Limited
Zeal Rupani
Company Secretary
Investor and Analyst Presentation
18 June 2026
Disclaimer
This communication, except for the historical data, may contain forward-looking statements, including
words, phrases, numbers that set forth anticipated results based on management’s current plans and
assumptions. Forward-looking statements are based on current expectations and assumptions, which are
subject to risks and uncertainties that may cause results to differ materially from those expressed or
implied in those statements. The Company cautions investors that any such forward-looking statements
are not guarantees of future performance and that actual events or results may differ materially from those
statements. Actual events or results may differ materially because of factors that affect international
businesses and global economic conditions, as well as matters specific to the Company and the markets it
serves. The Company undertakes no obligation to update these statements whether as a result of new
information, future events or otherwise, except to the extent required by law.
Investor and Analyst Presentation
18 June 2026
AGENDA
• Business Results
• Strategy and Fiscal Updates
• Long term trends
• Landscape
Fiscal Results
2025-26
DELIVERED A STRONG YEAR
FY 2025-26 Strong, consistent Balanced Growth
16 +30%
SALES PAT
Considering that the company, effective last year, changed its Financial Year from July 1 –June 30 to April 1 – March 31, the last Financial Year of the Company covered a period of 9
months, from July 1, 2024, to March 31, 2025. The company performance has therefore been indexed versus the comparable 12-months period in the last year (April 1,2024, to March 31,
2025). The performance versus a 9-month past fiscal will not be comparable.
INTEGRATED
GROWTH
STRATEGY
PORTFOLIO
PERFORMANCE DRIVES
BRAND CHOICE
SUPERIORITY
ORGANIZATION TO WIN WITH CONSUMERS
EMPOWERED • AGILE
ACCOUNTABLE
CONSTRUCTIVE
DISRUPTION
PRODUCTIVITY
ACROSS OUR BUSINESS
TO FUEL INVESTMENTS
PORTFOLIO
PERFORMANCE DRIVES
BRAND CHOICE
VITAMIN B
IRON VITAMIN E
(Nerve Health)
PORTFOLIO
VITAMIN B
Trusted, Quality, Highly NASAL CARE OMEGA - 3
COMPLEX
Recommended Brands
SUPERIORITY
TO WIN WITH CONSUMERS
SUPERIORITY TO WIN WITH
CONSUMERS
RETAIL
PRODUCT PACKAGING COMMUNICATION
CONSUMER &
EXECUTION
CUSTOMER
VALUE
Superior Innovations To Delight Consumers
PRODUCT
Easy-To-Consume Symptomatic Relief Superior
Iron Supplement from Nerve Pain Fatty Liver Solution
Packaging that educates, and
stands out in store
PACKAGING
BEFORE AFTER
LIG Copy with subs
RETAIL
EXECUTION
PRODUCTIVITY
TO FUEL INVESTMENTS
PRODUCTIVITY
INTEGRATED INTO THE STRATEGY
Delivering the same or better output measures…
with lower spending or resource investment.
AD SPEND &
MATERIALS MANUFACTURING OVERHEAD
PROMOTION
INR 35 crores productivity savings for FY 25/26
CONSTRUCTIVE
DISRUPTION
ACROSS THE BUSINESS
CONSTRUCTIVE DISRUPTION
ACROSS THE BUSINESS
Health Care
Practitioners/
LEVERAGING EXTRA URBAN
Health Care
EMERGING COVERAGE
Organizations /
CHANNELS EXPANSION
Chemist +
(E-pharmacies, E-com, Q-Com)
DISTRIBUTOR
PARTNERSHIPS
Winning model enabling Available to consumers Expanding reach to white-
last mile reach where they are space extra urban
markets
ORGANIZATION
EMPOWERED • AGILE •
ACCOUNTABLE
Prioritizing Employee Wellbeing
Delivering Superior Employee Value Equation
OUR FOCUS AREAS
Healthcare Healthcare
Accessibility Awareness
Improving Creating
Healthcare healthcare
SUPPORTING ACCESS TO HEALTH accessibility awareness for
CARE FACILITIES AND AWARENESS IN through mobile uptake of
UNDERSERVED COMMUNITIES medical units Nutrition, Hygiene
SINCE 2019 across 11 states & maternal care
Partners
15,00,000+
Lives impacted
DRIVING HEALTHCARE ACCESS
Mobile Health Care Units Special Boat Clinic
1.8+L 1.1+L
25+K
Free Treatments Kilometers
VISITS
FY26 Travelled
DRIVING HEALTHCARE AWARENESS
Yes To Poshan Initiative Healthcare For Children
55K 4000+ ~20K 30+
Lives Malnourished Children CCIs Supported
Villages
Impacted Children Impacted Each Year
LONG TERM
TRENDS
SUPERIOR RESULTS OVER THE PAST 5 YEARS
7 +42%
+ % + %
CAGR
CAGR Increase in
NET SALES
Note: 1) Basis Published results; 2) Net Sales refers to revenue from operations; 3) PAT Excluding OCI; 4) ROE = PAT/ Avg. Equity
SUPERIOR RESULTS OVER THE PAST 5 YEARS
REVENUE FROM OPERATIONS (in INR Crs) PAT (in INR Crs)
1,408
1,008
2021 2022 2023 2024 2025* 2026 2021 2022 2023 2024 2025* 2026
Note: 1) *FY 24-25 was a 9-month year due to Fiscal Year change. For comparability, considered 12-month period from Apr 24 to Mar 26. 2) Basis Published results;
3) Net Sales refers to revenue from operations; 4) PAT Excluding OCI [PAT – Profit After Tax; OCI – Other Comprehensive Income]
CREATING SUPERIOR SHAREHOLDER VALUE
July 2016 Oct 2017 Jan 2019 Apr 2020 July 2021 Oct 2022 Jan 2024 Apr 2025 Mar 2026